{{refimprove|date=September 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451565418
| IUPAC_name = 1-[(5-Fluoropentyl)-1''H''-indol-3-yl]-(naphthalen-1-yl)methanone
| image = AM-2201.svg

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I
| legal_NZ = Temporary Class 
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 335161-24-5
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 53393997
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24751884
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = TBJ0966F1O

<!--Chemical data-->
| C=24 | H=22 | F=1 | N=1 | O=1
| molecular_weight = 359.44 g/mol
| smiles = O=C(C1=CN(CCCCCF)C2=C1C=CC=C2)C3=CC=CC4=C3C=CC=C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H22FNO/c25-15-6-1-7-16-26-17-22(20-12-4-5-14-23(20)26)24(27)21-13-8-10-18-9-2-3-11-19(18)21/h2-5,8-14,17H,1,6-7,15-16H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ALQFAGFPQCBPED-UHFFFAOYSA-N
}}

'''AM-2201''' ('''1-(5-fluoropentyl)-3-(1-naphthoyl)indole''') is a [[recreational drug|recreational]] [[designer drug]] that acts as a potent but nonselective [[full agonist]] for the [[cannabinoid receptor]].<ref>{{cite journal | title=Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids | journal=Australian Journal of Chemistry | year=2015 | volume=68 | pages=4–8 | doi=10.1071/CH14198 | first1=S. M. | last1=Wilkinson | url=http://www.publish.csiro.au/?paper=CH14198 | last2=Banister | first2=S. D. | last3=Kassiou | first3=M. | issue=1}}</ref> It is part of the [[List of AM cannabinoids|AM series of cannabinoids]] discovered by [[Alexandros Makriyannis]] at [[Northeastern University]].

==Hazards==
[[Convulsions]] have been reported<ref>{{cite journal | author1=David McQuade | url=https://link.springer.com/article/10.1007%2Fs00228-012-1379-2 | title=First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201 | date=March 2013 | author2=Simon Hudson | author3=Paul I. Dargan | author4=David M. Wood | journal=European Journal of Clinical Pharmacology | volume=69 | issue=3 | pages=373–376 | doi=10.1007/s00228-012-1379-2 | pmid=22936123}}</ref> including at doses as low as 10&nbsp;mg.<ref>{{cite web | url=https://erowid.org/experiences/exp.php?ID=89294 | title=The Night I Killed My Friends | work=Erowid.org | date=20 February 2011 | accessdate=11 June 2012 | author=ekaJ}}</ref>

Recreational use of AM-2201 in the United States has led to it being specifically listed in a proposed 2011 amendment to the [[Controlled Substances Act]], aiming to add a number of synthetic drugs into [[Controlled Substances Act#Schedule I controlled substances|Schedule I]].<ref>[https://www.gpo.gov/fdsys/pkg/BILLS-112hr1254ih/pdf/BILLS-112hr1254ih.pdf Synthetic Drug Control Act of 2011].  H.R. 1254, 112th Congress, 1st Session (2011).</ref> The [[acute toxicity]] and long term side effects associated with the use of AM-2201 are acute kidney failure, brain damage, strokes, convulsions, seizures, rhabdomyolysis, and death.<ref>[https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm Acute Kidney Injury Associated with Synthetic Cannabinoid Use, Multiple States, 2012].  CDC morbitidy and mortality weekly report 2012.</ref><ref>[https://www.forbes.com/sites/melaniehaiken/2013/06/29/spice-or-synthetic-marijuana-may-cause-psychosis-brain-and-kidney-damage/#326aa1a438ab Forbes Synthetic Marijuana May Cause Psychosis, Brain and Kidney Damage]. Forbes report, Synthetic Marijuana Linked to Psychosis, Brain, and Kidney Damage. 2013</ref><ref>{{cite journal | url=http://clinicalschizophrenia.org/doi/10.3371/CSRP.DUDE.031513 | title=Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use | author1=Dante Durand | author2=Leticia L. Delgado | author3=Dhizarah Matus de la Parra-Pellot | author4=Diana Nichols-Vinueza | journal=Clinical Schizophrenia & Related Psychoses | date=January 2015 | volume=8 | issue=4 | pages=205-208 | doi=10.3371/CSRP.DUDE.031513 | pmid=23518784}}</ref><ref>[http://www.bgdailynews.com/news/testing-shows-h-incense-can-severely-damage-organs/article_b88b274d-d64f-55c1-89b1-12077848a302.html Bowling Green Daily News Report 2011].  Bowling Green Daily News Report, 2011</ref><ref>[http://phys.org/news/2013-10-dangers-fake-marijuana-spice-k2.html Phys.org Report 2013].  Phys.org Website, 2013</ref>

==Pharmacology==
AM-2201 is a [[full agonist]] for [[cannabinoid receptor]]s. Affinities are: with a [[Dissociation constant|''K''<sub>i</sub>]] of 1.0&nbsp;nM at [[Cannabinoid receptor 1|CB<sub>1</sub>]] and 2.6&nbsp;nM at [[Cannabinoid receptor 2 (macrophage)|CB<sub>2</sub>]].<ref name="WO 2001 28557 A1">{{Ref patent2 | country = WO | number = 0128557 | status = granted | title = Cannabimimetic indole derivatives | pubdate = 2001-04-26 | gdate = 2001-06-07 | pridate= 1999-10-18 | inventor = Makriyannis A, Deng H | assign1= }}</ref> The 4-methyl [[Functional analog (chemistry)|functional analog]] [[MAM-2201]] probably has similar affinities.{{or|date=June 2015}} AM-2201 has an EC<sub>50</sub> of 38&nbsp;nM for human CB<sub>1</sub> receptors, and 58&nbsp;nM for human CB<sub>2</sub> receptors.<ref name="ACS 2015">{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00107 | date=August 2015 | first1=S. D. | first10=M. | first11=M. | first12=I. S. | first13=M. | first2=J. | first4=A. | last5=Longworth | first5=M. | last6=Wilkinson | first6=S. M. | last1=Banister | last11=Connor | last12=McGregor | last13=Kassiou | title=Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 | last2=Stuart | last3=Kevin | first3=R. C. | last4=Edington | last7=Beinat | first7=C. | last8=Buchanan | first8=A. S. | last9=Hibbs | first9=D. E. | journal=ACS Chemical Neuroscience | last10=Glass | volume=6 | issue=8 | pages=1445–1458 | doi=10.1021/acschemneuro.5b00107 | pmid=25921407}}</ref> AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3&nbsp;mg/kg, comparable to the potency of [[JWH-018]] in rats, suggesting potent cannabinoid-like activity.<ref name = "ACS 2015" />

===Pharmacokinetics===
{{Refimprove section|date=July 2012}}
{{see also|JWH-018#Pharmacokinetics}}
AM-2201 [[metabolism]] differs only slightly from that of [[JWH-018]]. AM-2201 ''N''-[[dealkylation]] produces fluoropentane instead of [[pentane]] (or plain [[alkane]]s in general).{{citation needed|date=February 2014}}

==Detection==
A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.<ref>[http://forendex.southernforensic.org/index.php/detail/index/1097 Southern Association of Forensic Scientists]</ref>

==See also==
* [[AM-694]]
* [[AM-1235]]
* [[AM-2232]]
* [[AM-2233]]
* [[JWH-018]]
* [[SDB-005]]
* [[THJ-018]]
* [[THJ-2201]]
* [[MEPIRAPIM]]
* [[NM-2201]]

==References==
<references />

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Cannabinoids]]
[[Category:Naphthoylindoles]]
[[Category:Fluoroalkanes]]
[[Category:AM cannabinoids]]
[[Category:Designer drugs]]
[[Category:CB1 receptor agonists]]
[[Category:CB2 receptor agonists]]